Ofatumumab and Bortezomib in Subjects With Relapsed CD20+Diffuse Large B Cell, Follicular, or Mantle Cell Lymphoma
Status:
Terminated
Trial end date:
2013-07-01
Target enrollment:
Participant gender:
Summary
This phase II trial studies how well giving ofatumumab together with bortezomib works in
treating patients with relapsed diffuse large B cell lymphoma (DLBCL), follicular lymphoma
(FL), or mantle cell lymphoma (MCL). Monoclonal antibodies, such as ofatumumab, can block
cancer growth in different ways. Some block the ability of cancer cells to grow and spread.
Others find cancer cells and help kill them or carry cancer-killing substances to them.
Bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for
cell growth. Giving ofatumumab together with bortezomib may help kill more cancer cells
Phase:
Phase 2
Details
Lead Sponsor:
OHSU Knight Cancer Institute
Collaborators:
GlaxoSmithKline Millennium Pharmaceuticals, Inc. National Cancer Institute (NCI)